Clinical Research
Filter News
Found 126,644 articles
-
Zymo Research Releases Open-Source Bioinformatics Pipeline for SARS-CoV-2 Variant Detection in Wastewater
5/11/2021
Early Release of the VirSieve™ Bioinformatics Pipeline Will Promote Collaboration in Environmental SARS-CoV-2 Research
-
Sequana Medical Announces Strong Top-Line Results from RED DESERT alfapump DSR® Study and Expansion of DSR® Development Programme
5/11/2021
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces positive top-line results from the RED DESERT study with repeated dose alfapump DSR® therapy in diuretic-resistant heart failure patients.
-
Caption Health's AI-Guided Ultrasound Deployed in U.S. Navy's CHARM 2.0 Study to Evaluate Cardiac Impact of COVID-19
5/11/2021
Caption Health, a leading medical artificial intelligence company driving better health outcomes by increasing access to ultrasound, shared that its Caption AI ultrasound technology is being utilized by the United States Naval Medical Research Center for the second phase of its COVID-19 Health Action Response for Marines study, now underway.
-
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
5/11/2021
ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that a leading cancer research institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, has published results of new work undertaken in triple negative breast cancer patients.
-
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
5/11/2021
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma and renal cell carcinoma and other type of tumors will be enrolled.
-
Over the past year, the world at large has become more familiar with mRNA technology thanks to vaccines developed against COVID-19. Now the world will be introduced to a new type of RNA-based medicine called Endless RNA, or eRNA for short.
-
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.
-
The CDC says that COVID-19 is an airborne threat, stating that transmission and subsequent infection can occur via inhalation of very fine respiratory droplets and aerosolized particles.
-
Researchers are now concerned that the same health inequalities that have made certain racial and ethnic groups experience higher infection and death rates also drive disparities in treatment for long Covid.
-
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
-
Scientists are getting very close to discovering the cure for Parkinson’s disease. While the world only has treatments for prevention and symptom management to give patients a comfortable life, we might see that change soon.
-
SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic
5/10/2021
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria.
-
RVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough AwardAnnual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies
5/10/2021
RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Awards program
-
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
5/10/2021
- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of publication
-
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
5/10/2021
Strengthens investor syndicate with SV's Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs for dementia and other inflammatory conditions.
-
Bigfoot Biomedical® Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes
5/10/2021
Bigfoot Biomedical ® Receives FDA Clearance for Bigfoot Unity ™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes Integrated with Abbott’s FreeStyle ® Libre 2 system, the Bigfoot Unity System is the first and only to translate continuously monitored glucose data into on-demand insulin dose recommendations displayed right on the pen-cap screen for ease of use 1
-
Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC)
5/10/2021
Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, presents two clinical case reports supporting the broad potential of AC5 ® Advanced Wound System in chronic and non-healing wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Spring this week.
-
Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients
5/10/2021
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients.
-
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
5/10/2021
Cue Biopharma announced today interim clinical data, including a confirmed partial response (PR), from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with HPV+ R/M HNSCC.
-
PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
5/10/2021
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5 th .